Marcum Wealth LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Marcum Wealth LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 0.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,245 shares of the biopharmaceutical company’s stock after buying an additional 261 shares during the period. Marcum Wealth LLC’s holdings in Pfizer were worth $1,733,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Usca Ria LLC lifted its position in shares of Pfizer by 11.6% in the 2nd quarter. Usca Ria LLC now owns 504,526 shares of the biopharmaceutical company’s stock worth $19,757,000 after purchasing an additional 52,362 shares during the period. Cito Capital Group LLC lifted its position in shares of Pfizer by 59.6% in the 1st quarter. Cito Capital Group LLC now owns 38,831 shares of the biopharmaceutical company’s stock worth $1,407,000 after purchasing an additional 14,500 shares during the period. Advisor Group Holdings Inc. lifted its position in shares of Pfizer by 4.4% in the 2nd quarter. Advisor Group Holdings Inc. now owns 2,090,666 shares of the biopharmaceutical company’s stock worth $81,925,000 after purchasing an additional 88,276 shares during the period. Guggenheim Capital LLC lifted its position in shares of Pfizer by 2.8% in the 1st quarter. Guggenheim Capital LLC now owns 1,461,508 shares of the biopharmaceutical company’s stock worth $52,950,000 after purchasing an additional 40,497 shares during the period. Finally, Carolina Wealth Advisors LLC lifted its position in shares of Pfizer by 7.1% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 112,745 shares of the biopharmaceutical company’s stock worth $4,415,000 after purchasing an additional 7,456 shares during the period. 64.93% of the stock is owned by hedge funds and other institutional investors.

Pfizer stock traded up $0.25 during mid-day trading on Wednesday, reaching $44.96. 282,606 shares of the company traded hands, compared to its average volume of 30,836,189. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.12. Pfizer Inc. has a fifty-two week low of $33.36 and a fifty-two week high of $51.86. The company has a market capitalization of $252.08 billion, a price-to-earnings ratio of 19.18, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74. The firm’s fifty day moving average is $44.74 and its two-hundred day moving average is $40.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.10. The firm had revenue of $18.98 billion for the quarter, compared to analyst estimates of $17.54 billion. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. During the same quarter in the prior year, the business earned $0.78 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 4.12 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, July 29th. This represents a $1.56 annualized dividend and a dividend yield of 3.47%. Pfizer’s dividend payout ratio (DPR) is presently 70.27%.

In related news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction dated Friday, July 30th. The stock was sold at an average price of $42.86, for a total value of $107,150.00. Following the completion of the transaction, the senior vice president now owns 11,430 shares in the company, valued at approximately $489,889.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 1,661 shares of Pfizer stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total value of $80,226.30. The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.

Several equities research analysts have recently weighed in on PFE shares. Mizuho upped their price target on shares of Pfizer from $42.00 to $43.00 and gave the stock a “neutral” rating in a research report on Friday, July 30th. SVB Leerink reiterated a “hold” rating and set a $49.00 price objective on shares of Pfizer in a research note on Tuesday. Royal Bank of Canada set a $44.00 price objective on shares of Pfizer in a research note on Thursday, July 29th. The Goldman Sachs Group set a $48.00 price objective on shares of Pfizer in a research note on Thursday, July 29th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a research note on Monday. Eleven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $42.77.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Story: What are Institutional Investors?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.